

ASX ANNOUNCEMENT

ADMEDUS ANNOUNCES PLACEMENT & RIGHTS ISSUE OF \$18.3M

- Oversubscribed placement for \$10M
- 1:9 renounceable rights issue to existing shareholders to raise a further \$8.3M
- Capital places the Company in a strong financial position
- Targeting sustainable profitability in FY18

Brisbane, Australia 29 July 2016

Admedus Limited (the Company) (ASX: AHZ) is pleased to announce that it has secured firm commitments for a oversubscribed \$10M private placement of ordinary shares to new institutional and existing and sophisticated investors at an issue price of \$0.33.

The Company will also undertake a 1:9 renounceable rights issue of ordinary shares at an issue price of \$0.33 to raise a total of \$18.3M (before costs). Shareholders on the register at 5pm (WST) on 15 August 2016 will be entitled to participate in the rights issue. More information regarding the rights issue will be set out in the Prospectus, to be mailed to eligible shareholders in accordance with the timeline below. Patersons Securities Limited acted as Lead Manager to the Offer.

Admedus Chairman and Interim CEO, Mr Wayne Paterson, commented: *"This capital raise will allow us to continue our current strong sales growth and roll-out additional products into the cardiovascular markets, whilst implementing our corporate strategy of tighter expenditure control. The completion of this capital raise, in addition to the implementation of our recent strategic review, removes any concerns about the finances of Admedus and places the Company in a very strong position to achieve sustainable profitability for the 2018 financial year (if not before) and beyond."*

Admedus will use the funds raised from the placement and the rights issue to execute its recently announced corporate restructuring with the majority allocated for working capital. In addition, funds will be used for the purposes of:

- Scale up of manufacturing to meet market demand;
- New product and IP development;
- New market expansion across emerging markets and new product ranges;
- Further investment and development in immunotherapy programmes in conjunction with Professor Ian Frazer; and
- Clinical and post market studies.

The indicative timetable for the rights issue is set out below. Please note that this timetable is indicative only. The Company reserves the right to amend this indicative timetable at any time, subject to the Corporations Act 2001 (Cth) and the ASX Listing Rules.

Option holders should note that in order to be able to participate in the rights issue they will need to exercise their options. Further details will be provided to option holders shortly.

* Subject to the ASX Listing Rules, the Directors reserve the right to extend the Closing Date for the rights issue at their discretion. Should this occur, the extension will have a

Event	Date
'Ex' Date (Date from which shares commence trading without the entitlement to participate in the rights issue)	12 August 2016
Record Date at 5.00pm WST (Date for determining entitlements of eligible shareholder to participate in the rights issue)	15 August 2016
Prospectus dispatched to eligible shareholders	18 August 2016
Opening Date	18 August 2016
Closing Date at 3.00pm WST*	29 of August 2016
Issue Date (Allocation of new shares)	5 September 2016

consequential effect on the anticipated date of issue for the new shares.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

Website: www.admedus.com

Blog: www.admedus.com/au/category/news/

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 (0)8 9266 0100

Media:

Shevaun Cooper | PR Manager | Admedus Limited

Tel: +61 (0) 417 985 599 | Email: scooper@admedus.com

Media Europe

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

US Investor

Rx Communications Group, LLC

Melody A. Carey

+1 917 322 2571

mcarey@rxir.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com